Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To test discrimination of cancer from non-cancer, the area under the receiver operating characteristic curves determined for cancer antigen 125 (CA125), miR-145, miR-200c, miR-21, and miR-93 were 0.801 (<i>p</i><0.001), 0.910 (<i>p</i><0.001), 0.802 (<i>p</i><0.001), 0.585 (<i>p</i>=0.303), and 0.755 (<i>p</i>=0.002), respectively.
|
31205555 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-93 could act as an effective diagnostic and prognostic factor for cancer patients.
|
30390344 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High miR-93 and miR-200a levels in cancer cells of PDAC were associated with better differentiation, and miR-200a expression in benign tissue with excellent RFS.
|
30537722 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Abbreviations: ACTB: actin beta; ATG4B: autophagy related 4B cysteine peptidase; ATG5: autophagy related 5; BECN1: beclin 1; CL: classical; CQ: chloroquine diphosphate; CSCs: cancer stem cells; GBM: glioblastoma; GSCs: glioma stem-like cells; HEK: human embryonic kidney; IB: immunoblotting; IF: immunofluorescent staining; IR: irradiation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MES: mesenchymal; MIR93: microRNA 93; MIRC: a control miRNA; miRNA/miR: microRNA; MTOR: mechanistic target of rapamycin kinase; NSC: NSC185085; PN: proneural; qRT-PCR: quantitative reverse transcription-polymerase chain reaction; Rap: rapamycin; SQSTM1/p62: sequestosome 1; TCGA: the cancer genome atlas; TMZ: temozolomide; WT: wild type; ZIP93: lentiviral miRZIP targeting MIR93; ZIPC: lentiviral miRZip targeting control miRNA.
|
30654687 |
2019 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A microRNA associated with cancer (oncomiR), miR-93-5p, has recently been found to play an essential role in tumorigenesis and progression of various carcinomas, including liver cancer.
|
29361788 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, hsa-miR-93 was upregulated in <i>SNHG16</i>-overexpressed HCC cells to examine its effect on <i>SNHG16</i>-mediated cancer cell functional regulation in HCC.
|
30573973 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-93-5p (miR-93-5p) dysregulation has been reported in many types of human cancer.
|
29309884 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
miR-93 upregulation and CDKN1A downregulation may be both associated with the development, progression and patients' prognosis of cervical cancer. miR-93/CDKN1A axis may also play an important role in the malignancy of cervical cancer cells, suggesting its potential as a therapeutic target for this cancer.
|
30098344 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerous reports have indicated that microRNA‑93‑5p (miR‑93‑5p) is involved in the development and progression of human cancer, including non‑small cell lung, gastric and breast cancer; however, the role of miR‑93‑5p in retinoblastoma (RB) remains unknown.
|
30365088 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-93-5p (miR-93-5p) has been identified as an oncogenic miRNA in a variety of human malignancies and involved in tumor angiogenesis in astrocytoma.
|
29291009 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-93 (miR-93) is an oncomiR in many types of human cancer, exerting pivotal effects in the development and progression of malignancies, including NSCLC.
|
28382150 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-93-5p (miR-93) is a novel oncogenic microRNA (miRNA) and is elevated in diverse human malignancies.
|
25578493 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies have shown that miR-93's targetome in cancer has not been fully defined.
|
25649143 |
2015 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Specifically, we demonstrate that three of the MICB-targeting microRNAs: miR-20a, miR-17-5p and miR-93, also target the same site in the 3'UTR of TWIST1, a transcription factor implicated in cancer metastasis.
|
25426550 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-93 is oncogenic, but its targetome in cancer has not been fully defined.
|
24606633 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In "claudin(low)" SUM159 cells, expression of mir-93 induces Mesenchymal-Epithelial Transition (MET) associated with downregulation of TGFβ signaling and downregulates multiple stem cell regulatory genes, including JAK1, STAT3, AKT3, SOX4, EZH1, and HMGA2, resulting in cancer stem cell (CSC) depletion.
|
22685420 |
2012 |